INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 160 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,605,292 | +4161.6% | 1,542,896 | +2442.3% | 0.01% | – |
| Q2 2023 | $671,231 | -68.2% | 60,690 | -61.3% | 0.00% | -100.0% |
| Q1 2023 | $2,108,107 | +433.1% | 156,970 | +391.0% | 0.00% | – |
| Q4 2022 | $395,469 | +16.3% | 31,970 | +31.2% | 0.00% | – |
| Q3 2022 | $340,000 | +0.9% | 24,370 | 0.0% | 0.00% | – |
| Q2 2022 | $337,000 | -14.9% | 24,370 | 0.0% | 0.00% | – |
| Q1 2022 | $396,000 | -72.3% | 24,370 | -72.2% | 0.00% | -100.0% |
| Q4 2021 | $1,428,000 | +294.5% | 87,649 | +259.7% | 0.00% | – |
| Q3 2021 | $362,000 | -44.0% | 24,370 | -24.7% | 0.00% | – |
| Q2 2021 | $646,000 | +15.4% | 32,370 | +33.4% | 0.00% | – |
| Q1 2021 | $560,000 | -36.9% | 24,270 | -32.5% | 0.00% | – |
| Q4 2020 | $888,000 | -40.4% | 35,970 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $1,491,000 | -15.6% | 35,970 | -2.4% | 0.00% | 0.0% |
| Q2 2020 | $1,766,000 | -22.9% | 36,870 | +1.4% | 0.00% | -50.0% |
| Q1 2020 | $2,290,000 | -49.2% | 36,370 | 0.0% | 0.00% | -33.3% |
| Q4 2019 | $4,507,000 | +95.4% | 36,370 | +4.6% | 0.00% | +200.0% |
| Q3 2019 | $2,307,000 | -14.9% | 34,770 | +2.1% | 0.00% | -50.0% |
| Q2 2019 | $2,711,000 | -18.9% | 34,070 | +14.1% | 0.00% | 0.0% |
| Q1 2019 | $3,341,000 | -52.3% | 29,870 | -57.0% | 0.00% | -60.0% |
| Q4 2018 | $7,002,000 | +70.1% | 69,470 | +113.3% | 0.01% | +66.7% |
| Q3 2018 | $4,116,000 | -52.2% | 32,570 | -68.2% | 0.00% | -50.0% |
| Q2 2018 | $8,607,000 | +43.5% | 102,570 | +5.2% | 0.01% | +20.0% |
| Q1 2018 | $5,999,000 | +1008.9% | 97,514 | +953.2% | 0.01% | – |
| Q4 2017 | $541,000 | -0.4% | 9,259 | -1.1% | 0.00% | – |
| Q3 2017 | $543,000 | -52.6% | 9,359 | -1.1% | 0.00% | -100.0% |
| Q2 2017 | $1,145,000 | +13.6% | 9,459 | +6.2% | 0.00% | 0.0% |
| Q1 2017 | $1,008,000 | +3.8% | 8,909 | -0.3% | 0.00% | 0.0% |
| Q4 2016 | $971,000 | -35.9% | 8,939 | -2.8% | 0.00% | 0.0% |
| Q3 2016 | $1,514,000 | -19.0% | 9,200 | -29.8% | 0.00% | -50.0% |
| Q2 2016 | $1,869,000 | +55.1% | 13,100 | +39.6% | 0.00% | +100.0% |
| Q1 2016 | $1,205,000 | -14.8% | 9,383 | -0.9% | 0.00% | 0.0% |
| Q4 2015 | $1,414,000 | -10.0% | 9,470 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $1,571,000 | -26.9% | 9,470 | +6.4% | 0.00% | -50.0% |
| Q2 2015 | $2,148,000 | +0.2% | 8,900 | +17.1% | 0.00% | 0.0% |
| Q1 2015 | $2,143,000 | +84.4% | 7,600 | +2.0% | 0.00% | +100.0% |
| Q4 2014 | $1,162,000 | -35.4% | 7,450 | -2.0% | 0.00% | -50.0% |
| Q3 2014 | $1,799,000 | -88.2% | 7,600 | -88.2% | 0.00% | -84.6% |
| Q2 2014 | $15,199,000 | -70.5% | 64,229 | -58.8% | 0.01% | -70.5% |
| Q1 2014 | $51,469,000 | +160.6% | 156,067 | -46.0% | 0.04% | +144.4% |
| Q4 2013 | $19,751,000 | -4.1% | 289,259 | -3.1% | 0.02% | -10.0% |
| Q3 2013 | $20,599,000 | +43.0% | 298,410 | -7.1% | 0.02% | +33.3% |
| Q2 2013 | $14,404,000 | – | 321,239 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |